CORPUS CHRISTI, Texas and OKLAHOMA CITY, May 11 /PRNewswire-FirstCall/ -- Donald S. Robbins, CEO of Consortium Service Management Group, Inc. (BULLETIN BOARD: CTUM or CTUM.OB) , announced today a United States patent on the “System and Method of Control of Tissue Welding” has been issued for the company’s platform live-biological-tissue bonding / welding technology.
The patent issuance followed the issuance of our first US patent and an Australian patent as well as the successful completion of more than 2,000 human surgeries at three hospitals in clinical trials in Ukraine. Robbins considers the patent issuance a significant milestone in the continued development of the company’s live biological tissue bonding platform technology.
The three Ukraine hospitals are using the technology daily for open and laparoscopic surgical procedures and techniques. The procedures so far have involved the bonding and reconnecting of incised or separated human tissues in the following body areas -- nasal septum, intestine, stomach, skin, gall bladder, liver, spleen, lung, blood vessels, nerves, alba linea, uterus, fallopian tube, ovary and testicles -- while restoring the normal function of the organ or tissue.
In addition, the technology will be presented in a private demonstration at the University of Louisville, Louisville, KY next week. Attending the demonstrations will be a number of medical professionals, medical device companies and other industry experts. The demonstrations will include leak- proof, smokeless and bloodless reconnection of organs including end-to-end and end-to-side reconnection of intestine, liver resection, spleen, gall bladder, large blood vessels and surgery techniques for other organs. Burst strength comparisons will be performed.
The tissue bonding device bonds through Radiofrequency fusion and reconnects living soft biological tissue (organs) without the use of foreign matters or conventional wound closing devices such as sutures, staples, sealant, or glues. The technology leaves little or no scar visible to the naked eye after a few months. Unlike other tissue coagulation methods that tend to destroy tissue by charring, searing and necrosis, the CTUM patented technology bonds and reconnects incised tissue and avoids charring, searing and necrosis, using a patented low heat delivery method aimed at restoration of the normal functions of the live organs and tissue.
United States and Australia patents have been issued with other US and foreign patents pending. CTUM maintains a team of academicians, professors, researchers, surgeons, engineers, technicians and clinical test facilities in Ukraine and has offices in Corpus Christi, Texas; Oklahoma City, Oklahoma and Kiev, Ukraine.
CTUM owns the technology and exclusive world rights to the medical device through Live Tissue Connect Inc, a subsidiary corporation formed for the development and exploitation of the platform technology.
CSMG’s stock is quoted on the Internet at http://www.otcbb.com/ . Its website is http://www.ctum.com/ , and its E-mail address is publicrelations@ctum.com .
Consortium Service Management Group, Inc.
CONTACT: Donald S. Robbins, President and CEO, +1-361-887-7546, orGordon W. Allison, Executive Vice President, +1-405-748-7424, both ofConsortium Service Management Group, Inc.
